TW201929884A - Polysaccharides of brown algae, method of producing the same and application thereof - Google Patents
Polysaccharides of brown algae, method of producing the same and application thereof Download PDFInfo
- Publication number
- TW201929884A TW201929884A TW106146615A TW106146615A TW201929884A TW 201929884 A TW201929884 A TW 201929884A TW 106146615 A TW106146615 A TW 106146615A TW 106146615 A TW106146615 A TW 106146615A TW 201929884 A TW201929884 A TW 201929884A
- Authority
- TW
- Taiwan
- Prior art keywords
- crude extract
- brown algae
- producing
- fucoidan
- algae polysaccharide
- Prior art date
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本發明是有關於一種多醣及其製造方法,特別是有關於一種具有抑制脂質合成及抑制促炎因子功效的褐藻多醣及其製造方法暨應用。 The invention relates to a polysaccharide and a preparation method thereof, in particular to a brown algae polysaccharide having the effects of inhibiting lipid synthesis and inhibiting proinflammatory factors, a preparation method thereof and application thereof.
飼料添加物是指經中央主管機關公告,為提高飼料效用,保持飼料品質,促進家畜、家禽、水產動物發育,保持其健康或其他用途,添加於飼料且不含藥品之非營養性物質。飼料添加物包括微生物、酵素、保存劑及抗氧化劑、碘化蛋白、酸度調節劑、品質提升劑(乳化劑、打粒劑、著色劑、風味劑、抗結塊劑及黴菌毒素吸附劑)、畜/水產技術添加物、藥物等,其中含藥物飼料添加物一般包括抗生素製品、非抗生素製品及卡巴得(Carbadox)製品等。 Feed additives refer to non-nutritive substances that have been announced by the central competent authority to improve the efficiency of feed, maintain feed quality, promote the development of livestock, poultry, and aquatic animals, maintain their health or other uses, and add to feed without chemicals. Feed additives include microorganisms, enzymes, preservatives and antioxidants, iodinated proteins, acidity regulators, quality enhancers (emulsifiers, granulating agents, colorants, flavoring agents, anti-caking agents and mycotoxin adsorbents), Animal/aquatic technology additives, drugs, etc., including drug feed additives generally include antibiotic products, non-antibiotic products, and Carbadox products.
在實際使用時,高達27%的飼料添加物用的是抗生素,但細菌對抗生素容易產生抗藥性,近年陸續爆發各種動物疾病,代表含藥物飼料添加物有必要刪減。至於其他化學性飼料添加物,各國雖有限制及規範,但其原料存在重 金屬污染以及化學毒性等問題,而化學性飼料添加物本身也有於環境或人體殘留或累積毒性等問題,實有必要開發天然成分的飼料添加物。 In actual use, up to 27% of feed additives use antibiotics, but bacteria are resistant to antibiotics. In recent years, various animal diseases have emerged, indicating that it is necessary to delete the drug-containing feed additives. As for other chemical feed additives, although there are restrictions and specifications in various countries, the raw materials are heavy. Metal contamination and chemical toxicity, and chemical feed additives themselves have problems such as environmental or human residual or cumulative toxicity. It is necessary to develop feed additives for natural ingredients.
臺灣四面環海,藻類資源非常豐富。依據藻體內的色素、儲藏物質等特徵,可將海藻分成藍綠藻(Cyanophyte)、綠藻(Chlorophyte)、褐藻(Phaeophyte)及紅藻等四大類。惟近來地球暖化,生長於潮間帶的部分大型海藻大量繁殖,不僅干擾漁民作業,造成海域、漁港作業船隻的困擾,這些藻種也較少被轉作食材,乏人問津,幾乎被作為飼料或者是廢棄物。 Taiwan is surrounded by the sea and the algae resources are very rich. According to the characteristics of pigments and storage substances in the algae, the seaweed can be divided into four major categories: Cyanophyte, Chlorophyte, Phaeophyte, and Red Algae. Recently, the global warming, part of the large seaweed growing in the intertidal zone has been multiplied, which not only interferes with the fishermen's operations, but also causes troubles in the sea and fishing port operations. These algae species are also less converted into ingredients, which are rarely used as feed. Or it is waste.
目前有各種萃取褐藻多醣的方式。有一些萃取方式是將馬尾藻經高溫高壓處理(爆餅機)後,利用70~100℃之熱水萃取1至3小時後,所得之褐藻醣膠(即褐藻多醣)具有清除DPPH自由基且無藻腥味的功效。另一些方式則是利用100℃左右之熱水萃取馬尾藻約1至3小時(5%(w/w))後,再經酵素、酸化及化學修飾(添加硫酸根)處理,所得之硫酸化馬尾藻多醣具有抗腸病毒71型的功效。 There are various ways to extract brown algae polysaccharides. Some extraction methods are: after the high temperature and high pressure treatment (burst cake machine), after extracting with hot water of 70-100 ° C for 1 to 3 hours, the obtained fucoidan (ie, brown algae polysaccharide) has DPPH free radical scavenging and No algae smell. In other ways, after extracting Sargasso from about 1 to 3 hours (5% (w/w)) with hot water of about 100 °C, it is treated with enzyme, acidification and chemical modification (addition of sulfate) to obtain sulfation. Sargassum polysaccharide has anti-enteric virus type 71 effect.
然而,上述方式所得的褐藻多醣仍含有色素、藻蛋白及褐藻酸等,且分子量較大的褐藻多醣,通過腸胃道後不易被吸收,不僅降低生物利用率,更影響褐藻多醣的功效。有鑑於此,亟需提供一種褐藻多醣的新製程,改善傳統褐藻多醣之上述缺點,以拓展大型海藻的應用面。 However, the brown algae polysaccharide obtained in the above manner still contains a pigment, an algal protein, a brown alginic acid, etc., and the brown algae polysaccharide having a large molecular weight is not easily absorbed after the gastrointestinal tract, thereby not only reducing the bioavailability but also affecting the efficacy of the brown algae polysaccharide. In view of this, it is urgent to provide a new process for the brown algae polysaccharide, to improve the above-mentioned shortcomings of the traditional brown algae polysaccharide, and to expand the application surface of the large seaweed.
因此,本發明之一態樣是在提供一種褐藻多醣的製造方法,其利用熱水萃取步驟併用微波輔助萃取處理及/或超聲波輔助萃取處理,可提高褐藻多醣之純化量。 Therefore, one aspect of the present invention provides a method for producing a brown algae polysaccharide which can improve the purification amount of fucoidan by a hot water extraction step and a microwave assisted extraction treatment and/or an ultrasonic assisted extraction treatment.
本發明之另一態樣係在提供一種褐藻多醣,其係利用上述方法製得低分子量的褐藻多醣。 Another aspect of the present invention provides a fucoidan polysaccharide which is obtained by the above method to produce a low molecular weight fucoidan.
本發明之又一態樣係在提供一種組成物,包含有效劑量之上述褐藻多醣。 A further aspect of the invention provides a composition comprising an effective amount of the above-described fucoidan.
本發明之又另一態樣係在提供一種褐藻多醣用於製備抑制脂質合成及抑制促炎因子的醫藥組成物之用途,以抑制細胞的脂質合成反應及抑制腫瘤壞死因子(TNF)-α的產生。 Still another aspect of the present invention provides a use of a fucoidan polysaccharide for the preparation of a pharmaceutical composition for inhibiting lipid synthesis and inhibiting proinflammatory cytokines, for inhibiting cell lipid synthesis reaction and inhibiting tumor necrosis factor (TNF)-α produce.
根據本發明之上述態樣,提出一種褐藻多醣的製造方法。在一實施例中,上述褐藻多醣的製造方法可包括對乾燥海藻原料進行至少一前處理,以獲得第一粗萃取物。 接著,對第一粗萃取物進行熱水萃取步驟,以獲得第二粗萃取物,其中熱水萃取步驟係將第一粗萃取物浸於100℃之水中進行微波輔助萃取處理及/或超聲波輔助萃取處理,第一粗萃取物與水之液固比(mL/g)為10至20,且熱水萃取步驟進行不超過1小時。之後,對第二粗萃取物進行後處理,以去除第二粗萃取物之蛋白質、藻酸鹽並獲得褐藻多醣,其中褐藻多醣之分子量不大於3.2千道耳頓(kilo-dalton;kDa)。 According to the above aspect of the invention, a method for producing a brown algae polysaccharide is proposed. In one embodiment, the method for producing the fucoidan may include performing at least one pretreatment on the dried algal material to obtain a first crude extract. Next, the first crude extract is subjected to a hot water extraction step to obtain a second crude extract, wherein the hot water extraction step is to immerse the first crude extract in water at 100 ° C for microwave assisted extraction and/or ultrasonic assist In the extraction treatment, the liquid-solid ratio (mL/g) of the first crude extract to water is 10 to 20, and the hot water extraction step is carried out for no more than 1 hour. Thereafter, the second crude extract is post-treated to remove the protein, alginate of the second crude extract and obtain a brown algae polysaccharide, wherein the molecular weight of the fucoidan is not more than 3.2 kilo-dalton (kDa).
在本發明的實施例中,上述乾燥海藻原料可包括但不限於莢托馬尾藻(Sargassum siliquosum)、半葉馬 尾藻(S.hemiphyllum)及匍枝馬尾藻(S.polycystum)。 In an embodiment of the present invention, the dried seaweed material may include, but is not limited to, Sargassum siliquosum , S. hemiphyllum , and S. polycystum .
在本發明的實施例中,上述前處理包括可選擇性對乾燥海藻原料進行高溫高壓步驟。在高溫高壓步驟之後,更可選擇性對海藻粉進行粗萃取步驟以及去除溶劑步驟,以獲得粗原料。 In an embodiment of the invention, the pretreatment comprises selectively performing a high temperature and high pressure step on the dried algal material. After the high temperature and high pressure step, the seaweed powder is selectively subjected to a crude extraction step and a solvent removal step to obtain a crude raw material.
在本發明的實施例中,上述後處理包括去除蛋白質步驟、去除藻酸鹽步驟、層析法及/或部分水解法。 In an embodiment of the invention, the post-treatment described above includes a step of removing the protein, a step of removing the alginate, a chromatography, and/or a partial hydrolysis.
根據本發明之另一態樣,提出一種褐藻多醣,其係利用上述方法製得,其中該褐藻多醣之分子量不大於3.2kDa。 According to another aspect of the present invention, a brown algae polysaccharide is provided which is obtained by the above method, wherein the molecular weight of the fucoidan is not more than 3.2 kDa.
根據本發明之又一態樣,提出一種組成物,包含一有效劑量之褐藻多醣,其中該褐藻多醣之分子量不大於3.2kDa。 According to still another aspect of the present invention, a composition comprising an effective amount of fucoidan is provided, wherein the fucoidan has a molecular weight of not more than 3.2 kDa.
根據本發明之又另一態樣,提出一種褐藻多醣用於製備抑制脂質合成及抑制促炎因子的醫藥組成物之用途,其中該褐藻多醣之分子量不大於3.2kDa,以抑制細胞的脂質合成反應及腫瘤壞死因子(TNF)-α的產生。 According to still another aspect of the present invention, a use of a brown algae polysaccharide for preparing a pharmaceutical composition for inhibiting lipid synthesis and inhibiting proinflammatory cytokines is proposed, wherein the molecular weight of the fucoidan polysaccharide is not more than 3.2 kDa to inhibit cell lipid synthesis reaction. And the production of tumor necrosis factor (TNF)-α.
應用本發明之褐藻多醣及其製造方法,其利用熱水萃取步驟併用微波輔助萃取處理及/或超聲波輔助萃取處理,不僅提高褐藻多醣之純化量,且所得之低分子量的褐藻多醣具有抑制細胞的脂質合成反應及腫瘤壞死因子(TNF)-α產生的功效,可應用於製備抑制脂質合成及抑制促炎因子的醫藥組成物。 The brown algae polysaccharide of the present invention and the method for producing the same, which utilize the hot water extraction step and the microwave assisted extraction treatment and/or the ultrasonic assisted extraction treatment, not only improve the purification amount of the brown algae polysaccharide, but also obtain the low molecular weight fucoidan having the cell inhibiting effect. The lipid synthesis reaction and the effect of tumor necrosis factor (TNF)-α production can be applied to the preparation of a pharmaceutical composition for inhibiting lipid synthesis and inhibiting pro-inflammatory factors.
為讓本發明之上述和其他目的、特徵、優點與實施例能更明顯易懂,所附圖式之詳細說明如下: 〔圖1A〕至〔圖1I〕係繪示根據本發明一實施例利用不同濃度之製備例1的褐藻多醣及比較例1的第二粗萃取物於體外處理細胞的螢光顯微照片。 The above and other objects, features, advantages and embodiments of the present invention will become more apparent and understood. 1A to 1I are fluorescent micrographs of cells treated in vitro using different concentrations of the fucoidan of Preparation Example 1 and the second crude extract of Comparative Example 1 according to an embodiment of the present invention.
〔圖2A〕至〔圖2L〕係繪示根據本發明一實施例利用不同濃度之製備例1至製備例4的褐藻多醣於體外處理細胞的螢光顯微照片。 2A to 2L are fluorescent micrographs of cells treated with fucoidan of Preparation Examples 1 to 4 at different concentrations according to an embodiment of the present invention.
〔圖3〕係繪示圖2A至圖2L的細胞經流式細胞儀計算的相對吸收度長條圖。 [Fig. 3] is a graph showing the relative absorbance of cells of Fig. 2A to Fig. 2L calculated by flow cytometry.
〔圖4〕係繪示根據本發明一實施例於體外經LPS誘發發炎反應的細胞利用不同濃度之製備例1的褐藻多醣及比較例1的第二粗萃取物處理後的TNF-α含量長條圖。 [Fig. 4] shows that the cells in the LPS-induced inflammatory reaction in vitro have a long TNF-α content after treatment with different concentrations of the fucoidan of Preparation Example 1 and the second crude extract of Comparative Example 1 according to an embodiment of the present invention. Bar chart.
承前所述,本發明提供一種褐藻多醣及其製造方法,其利用熱水萃取步驟併用微波輔助萃取處理及/或超聲波輔助萃取處理,不僅提高褐藻多醣之純化量,且所得之低分子量的褐藻多醣具有抑制細胞的脂質合成反應及腫瘤壞死因子(TNF)-α產生的功效。 As described above, the present invention provides a brown algae polysaccharide and a method for producing the same, which utilizes a hot water extraction step and a microwave assisted extraction treatment and/or an ultrasonic assisted extraction treatment to improve not only the purification amount of the brown algae polysaccharide but also the low molecular weight fucoidan obtained. It has the effect of inhibiting cell lipid synthesis reaction and tumor necrosis factor (TNF)-α production.
本發明此處所稱的褐藻多醣係指由海藻原料經水萃取而得的產物。在一實施例中,上述褐藻多醣為低分子量且低硫酸根含量者,然以分子量不大於3.2千道耳頓 (kilo-dalton;kDa)且硫酸根含量低於20%之褐藻多醣為佳,又以分子量不大於3.2kDa且硫酸根含量低於19%之褐藻多醣為較佳。 The fucoidan polysaccharide referred to herein as a product refers to a product obtained by extracting seaweed raw material by water. In one embodiment, the above-mentioned fucoidan is low molecular weight and low sulfate content, and the molecular weight is not more than 3.2 thousand Daltons. (kilo-dalton; kDa) and fucoidan having a sulfate content of less than 20% are preferred, and fucoidan having a molecular weight of not more than 3.2 kDa and a sulfate content of less than 19% is preferred.
上述褐藻多醣可利用下述方法製得。在一實施例中,首先,對乾燥海藻原料進行前處理,以獲得粗原料。前述海藻原料可選擇性經水洗去除表面鹽分後,利用各種習知方式進行乾燥,例如以低於100℃之溫度乾燥數小時至數十小時,藉此獲得乾燥海藻原料。在上述實施例中,乾燥海藻原料可包括但不限於莢托馬尾藻(Sargassum siliquosum)、半葉馬尾藻(S.hemiphyllum)及匍枝馬尾藻(S.polycystum)。在另一例子中,乾燥海藻原料可例如莢托馬尾藻。 The above brown algae polysaccharide can be obtained by the following method. In one embodiment, first, the dried seaweed material is pretreated to obtain a crude material. The seaweed raw material may be optionally washed with water to remove surface salt, and then dried by various conventional methods, for example, drying at a temperature lower than 100 ° C for several hours to several tens of hours, thereby obtaining a dried seaweed raw material. In the above embodiments, the dried seaweed material may include, but is not limited to, Sargassum siliquosum , S. hemiphyllum , and S. polycystum . In another example, the dried seaweed material can be, for example, S.
在上述實施例中,適合的前處理可包括包含第一前處理。在一例子中,第一前處理可包括在140℃至250℃之溫度及之1.5kg/cm2至19kg/cm2之壓力下,對乾燥海藻原料進行高溫高壓處理達4秒至10秒,以獲得膨發海藻原料。在一例示中,高溫高壓處理可利用市售設備(例如高溫高壓爆餅機)進行,以獲得膨發海藻原料。 In the above embodiments, suitable pre-processing may include including a first pre-processing. In an example, the first pretreatment may include performing high temperature and high pressure treatment on the dried seaweed material at a temperature of 140 ° C to 250 ° C and a pressure of 1.5 kg / cm 2 to 19 kg / cm 2 for 4 seconds to 10 seconds. To obtain the raw material of the expanded seaweed. In an example, the high temperature and high pressure treatment can be carried out using commercially available equipment (for example, a high temperature and high pressure blasting machine) to obtain a swelled seaweed material.
在一些例子中,前述第一前處理之後,上述前處理更可選擇性對上述膨發海藻原料進行第二前處理,以獲得第一粗萃取物。 In some examples, after the first pre-treatment, the pre-treatment may selectively perform a second pretreatment on the expanded algae material to obtain a first crude extract.
在上述例子中,第二前處理包含粗萃取步驟以及去除溶劑步驟。在上述例子中,上述膨發海藻原料可直接進行粗萃取步驟。在另一些例子中,上述膨發海藻原料可選 擇性利用習知粉碎方法(例如研磨等)粉碎成海藻粉後,再對海藻粉進行粗萃取步驟。 In the above examples, the second pretreatment comprises a crude extraction step and a solvent removal step. In the above examples, the above-mentioned expanded seaweed material may be directly subjected to a crude extraction step. In other examples, the above-mentioned expanded seaweed raw material is optional After the pulverization into the seaweed powder by a conventional pulverization method (for example, grinding or the like), the seaweed powder is subjected to a crude extraction step.
在進行上述粗萃取步驟時,可將膨發海藻原料浸於極性溶液中(例如95%乙醇溶液),以例如10mL/g的液固比進行粗萃取4小時至24小時,可獲得粗萃取液。粗萃取步驟亦可去除膨發海藻原料所含的脂質、甘露醇(mannitol)、色素及部分鹽分。接著,可選擇性對粗萃取液進行固液分離步驟(例如離心)進行,藉此獲得第一粗萃取物。 In the above crude extraction step, the swelled seaweed material may be immersed in a polar solution (for example, a 95% ethanol solution), and subjected to crude extraction at a liquid-solid ratio of, for example, 10 mL/g for 4 hours to 24 hours to obtain a crude extract. . The crude extraction step also removes lipids, mannitol, pigments and partial salts contained in the expanded seaweed material. Next, the crude extract may be selectively subjected to a solid-liquid separation step (for example, centrifugation), whereby a first crude extract is obtained.
在一實施例中,獲得第一粗萃取物後,接著對第一粗萃取物進行熱水萃取步驟,以獲得第二粗萃取物。在此實施例中,熱水萃取步驟可將第一粗萃取物浸於100℃之水中併用微波輔助萃取處理及/或超聲波輔助萃取處理。在上述實施例中,第一粗萃取物與水之液固比(mL/g)可例如為10至25。在上述例子中,熱水萃取步驟進行的時間不超過1小時。 In one embodiment, after the first crude extract is obtained, the first crude extract is then subjected to a hot water extraction step to obtain a second crude extract. In this embodiment, the hot water extraction step may immerse the first crude extract in water at 100 ° C and use microwave assisted extraction and/or ultrasonic assisted extraction. In the above embodiment, the liquid-solid ratio (mL/g) of the first crude extract to water may be, for example, 10 to 25. In the above examples, the hot water extraction step is carried out for no more than one hour.
在上述實施例中,熱水萃取步驟併用微波輔助萃取處理及/或超聲波輔助萃取處理,可有效提升30%以上之褐藻多醣純化量。在其他實施例中,熱水萃取步驟併用微波輔助萃取處理可有效提升35%至45%的褐藻多醣產量。 In the above embodiment, the hot water extraction step and the microwave assisted extraction treatment and/or the ultrasonic assisted extraction treatment can effectively increase the purification amount of the brown algae polysaccharide by more than 30%. In other embodiments, the hot water extraction step and microwave assisted extraction treatment can effectively increase the yield of fucoidan from 35% to 45%.
在上述實施例中,微波輔助萃取處理可例如利用750W之微波功率處理第一粗萃取物,其中第一粗萃取物與水之液固比(mL/g)為15至25處理達5分鐘至20分鐘為宜,然以液固比(mL/g)15至20處理10分鐘至20分鐘為較 佳,又以液固比(mL/g)15至20處理10分鐘至15分鐘為更佳。在一實施例中,熱水萃取步驟併用微波輔助萃取處理可提升約45%之褐藻多醣純化量。 In the above embodiment, the microwave-assisted extraction treatment may treat the first crude extract, for example, with a microwave power of 750 W, wherein the liquid-solid ratio (mL/g) of the first crude extract to water is 15 to 25 treatments for 5 minutes to 20 minutes is appropriate, but liquid to solid ratio (mL / g) 15 to 20 treatment for 10 minutes to 20 minutes for comparison Preferably, it is more preferably treated with a liquid-solid ratio (mL/g) of 15 to 20 for 10 minutes to 15 minutes. In one embodiment, the hot water extraction step and microwave assisted extraction treatment increase the amount of fucoidan purified by about 45%.
在上述實施例中,超聲波輔助萃取處理可例如利用50至200瓦之超聲波能量處理第一粗萃取物。當第一粗萃取物與水之液固比(mL/g)為15至25時,以利用50至200瓦之超聲波能量處理達10分鐘至20分鐘為宜;然而,當第一粗萃取物與水之液固比(mL/g)為15至20時,以利用50至150瓦之超聲波能量處理10分鐘至15分鐘為較佳;又,當第一粗萃取物與水之液固比(mL/g)為15時,以利用100瓦之超聲波能量處理約10分鐘為更佳。倘若使用超過200瓦之超聲波能量處理第一粗萃取物超過20分鐘,第二萃取物所含的褐藻多糖將過度降解,而無法獲得預期純化量的褐藻多糖。 In the above embodiment, the ultrasonic assisted extraction treatment may treat the first crude extract, for example, with an ultrasonic energy of 50 to 200 watts. When the liquid-solid ratio (mL/g) of the first crude extract to water is 15 to 25, it is preferably treated with ultrasonic energy of 50 to 200 watts for 10 minutes to 20 minutes; however, when the first crude extract is used When the liquid-solid ratio (mL/g) to water is 15 to 20, it is preferably treated with ultrasonic energy of 50 to 150 watts for 10 minutes to 15 minutes; and, when the liquid ratio of the first crude extract to water is When (mL/g) is 15, it is more preferably treated with ultrasonic energy of 100 watts for about 10 minutes. If the first crude extract is treated with more than 200 watts of ultrasonic energy for more than 20 minutes, the fucoidan contained in the second extract will be excessively degraded, and the expected purified amount of fucoidan cannot be obtained.
在一實施例中,獲得第二粗萃取物後,可選擇性對第二粗萃取物進行透析達數小時至數十小時,以去除分子量低於10kDa的成分。在一些例示中,可選擇性對透析後的第二粗萃取物進行習知固液分離步驟(例如過濾),以去除第二粗萃取物之固形物。 In one embodiment, after the second crude extract is obtained, the second crude extract can be selectively dialyzed for hours to tens of hours to remove components having a molecular weight below 10 kDa. In some illustrations, a second solid extract after dialysis may be selectively subjected to a conventional solid-liquid separation step (eg, filtration) to remove solids from the second crude extract.
在一實施例中,於熱水萃取步驟後,可對第二粗萃取物進行後處理,以去除第二粗萃取物之蛋白質及藻酸鹽並獲得褐藻多醣。在一些例示中,前述後處理可包括但不限於去除蛋白質步驟、去除藻酸鹽步驟、層析法及/或部分水解法。 In one embodiment, after the hot water extraction step, the second crude extract may be post-treated to remove the protein and alginate of the second crude extract and obtain a brown algae polysaccharide. In some illustrations, the foregoing post-treatment may include, but is not limited to, a protein removal step, an alginate removal step, a chromatography method, and/or a partial hydrolysis method.
在一例示中,上述去除蛋白質步驟可包含在酸性(例如pH 3至pH 3.5)室溫環境下進行等電點沉澱達數小時,以去除第二粗萃取物所含的蛋白質。在上述例示中,第二粗萃取物可於pH 3的室溫環境下進行約4小時的等電點沉澱,以去除第二粗萃取物中約83%的蛋白質。 In one example, the step of removing protein may comprise isoelectric precipitation for several hours in an acidic (eg, pH 3 to pH 3.5) room temperature environment to remove proteins contained in the second crude extract. In the above exemplification, the second crude extract can be subjected to isoelectric precipitation for about 4 hours at room temperature of pH 3 to remove about 83% of the protein in the second crude extract.
在一例示中,上述去除藻酸鹽步驟可於第二粗萃取物中添加最終濃度20g/L至40g/L的氯化鈣(CaCl2),並於0℃至10℃之環境下進行靜置數小時後,再以固液分離的方式(例如離心)去除所含的藻酸鹽。在上述例示中,第二粗萃取物可利用最終濃度20g/L的氯化鈣處理,以去除約74%的藻酸鹽。 In an example, the alginate removal step may add a final concentration of 20 g/L to 40 g/L of calcium chloride (CaCl 2 ) to the second crude extract, and perform static at 0 ° C to 10 ° C. After a few hours, the alginate contained is removed by solid-liquid separation (for example, centrifugation). In the above illustration, the second crude extract may be treated with calcium chloride having a final concentration of 20 g/L to remove about 74% of the alginate.
在一例示中,上述層析法可包含利用陰離子交換管柱,以1M至4M的氯化鈉溶液為沖提液對第二粗萃取物進行層析。在上述例示中,第二粗萃取物可利用市售陰離子交換管柱並以2M的氯化鈉溶液為沖提液進行層析,以獲得回收率較高的褐藻多醣。 In one example, the chromatographic method can comprise chromatographing a second crude extract with a 1M to 4M sodium chloride solution as a rinse using an anion exchange column. In the above exemplification, the second crude extract can be chromatographed using a commercially available anion exchange column and a 2M sodium chloride solution as a extract to obtain a brown algae polysaccharide having a high recovery rate.
在一例示中,上述部分水解法可包含利用過氧化氫溶液處理上述所得之褐藻多醣,以獲得低分子量褐藻多醣。本發明此處所稱之低分子量褐藻多醣係指分子量不大於3.2千道耳頓(kilo-dalton;kDa)且硫酸根含量低於19%者,又以分子量不大於3.2kDa且硫酸根含量低於19%者為較佳。在此例示中,前述所得的褐藻多醣進一步利用0.025M至0.1M之過氧化氫溶液處理達30分鐘至120分鐘,可提高低分子量褐藻多醣的產率,其中以利用0.05M至 0.1M之過氧化氫溶液處理約60分鐘至120分鐘為較佳,又以利用0.1M之過氧化氫溶液處理約60分鐘為更佳。在上述處理後,可選擇性利用習知方式(例如吹氮、95%乙醇溶液清洗等),進一步去除褐藻多醣殘留的過氧化氫,惟此乃本發明所屬領域中具有通常知識者所熟知,故不另贅述。 In one example, the partial hydrolysis method may include treating the obtained fucoidan polysaccharide with a hydrogen peroxide solution to obtain a low molecular weight fucoidan. The low molecular weight fucoidan as referred to herein means a molecular weight of not more than 3.2 kilodaltons (kda) and a sulfate content of less than 19%, and a molecular weight of not more than 3.2 kDa and a sulfate content lower than that. 19% are preferred. In this illustration, the obtained fucoidan polysaccharide is further treated with a 0.025 M to 0.1 M hydrogen peroxide solution for 30 minutes to 120 minutes, and the yield of the low molecular weight fucoidan can be increased, wherein 0.05 M is utilized. It is preferred to treat the 0.1 M hydrogen peroxide solution for about 60 minutes to 120 minutes, and more preferably for about 60 minutes with a 0.1 M hydrogen peroxide solution. After the above treatment, the conventional method (for example, nitrogen blowing, 95% ethanol solution washing, etc.) may be selectively used to further remove the residual hydrogen peroxide of the fucoidan, which is well known to those of ordinary skill in the art to which the present invention pertains. Therefore, I will not repeat them.
上述所得之低分子量褐藻多醣經體外細胞實驗證明,確實具有抑制細胞的脂質合成反應及腫瘤壞死因子(TNF)-α產生的功效,可應用於醫藥組成物。以下利用數個實施例以說明本發明之應用,然其並非用以限定本發明,本發明技術領域中具有通常知識者,在不脫離本發明之精神和範圍內,當可作各種之更動與潤飾。 The low molecular weight fucoidan obtained above has been proved to have the effect of inhibiting cell lipid synthesis reaction and tumor necrosis factor (TNF)-α production by in vitro cell experiments, and can be applied to pharmaceutical compositions. The following examples are used to illustrate the application of the present invention, and are not intended to limit the present invention. Those skilled in the art can make various changes without departing from the spirit and scope of the present invention. Retouching.
此實施例使用源自澎湖的莢托馬尾藻製造低分子量的褐藻多醣。莢托馬尾藻主要含有78.26%的總醣、19.48%的硫酸鹽、6.09%的蛋白質、5.52%的藻酸鹽、4.41%的酚類化合物等。此實施例利用前處理、熱水萃取步驟及後處理,可提高低分子量的褐藻多醣之產量。 This example uses a S. cerevisiae derived from Lake Biwa to produce a low molecular weight fucoidan. S. cerevisiae mainly contains 78.26% of total sugar, 19.48% of sulphate, 6.09% of protein, 5.52% of alginate, 4.41% of phenolic compounds, and the like. This embodiment utilizes pretreatment, hot water extraction steps, and post treatment to increase the yield of low molecular weight fucoidan.
製備例1Preparation Example 1
製備例1係參照表1所示的條件進行。簡言之,製備例1選用莢托馬尾藻,經水洗去除附生植物及表面鹽份後,在60℃之環境下乾燥48小時,以獲得乾燥海藻原料。接下來,利用市售高溫高壓爆餅機,在140℃至250℃之溫 度及之1.5kg/cm2至19kg/cm2之壓力下對乾燥海藻原料進行高溫高壓處理達4秒至10秒,以獲得膨發海藻原料。 Preparation Example 1 was carried out under the conditions shown in Table 1. Briefly, in Preparation Example 1, S. cerevisiae was selected, and the epiphytes and surface salts were removed by washing with water, and then dried at 60 ° C for 48 hours to obtain dried algae raw materials. Next, using a commercially available high temperature and high pressure blasting machine, the dried seaweed material is subjected to high temperature and high pressure treatment at a temperature of 140 ° C to 250 ° C and a pressure of 1.5 kg / cm 2 to 19 kg / cm 2 for 4 seconds to 10 seconds. To obtain the raw material of the expanded seaweed.
然後,上述膨發海藻原料利用習知研磨設備進行研磨,以粉碎成海藻粉。之後,海藻粉(1g)以10mL/g的液固比浸於95%乙醇溶液中,於室溫靜置(粗萃取)4小時,去除所含的脂質、甘露醇、色素及部分鹽分,藉此獲得第一粗萃取物。 Then, the above-mentioned expanded seaweed material is ground by a conventional grinding apparatus to be pulverized into seaweed powder. Thereafter, the seaweed powder (1 g) was immersed in a 95% ethanol solution at a liquid-solid ratio of 10 mL/g, and allowed to stand at room temperature (crude extraction) for 4 hours to remove the contained lipid, mannitol, pigment, and part of the salt. This gave the first crude extract.
接下來,將第一粗萃取物浸於100℃之水中進行熱水萃取步驟,併用微波輔助萃取處理及/或超聲波輔助萃取處理,以獲得第二粗萃取物,其中第一粗萃取物與水之液固比(mL/g)為15,以750W之微波功率處理10分鐘。 Next, the first crude extract is immersed in water at 100 ° C for a hot water extraction step, and subjected to microwave-assisted extraction treatment and/or ultrasonic-assisted extraction treatment to obtain a second crude extract, wherein the first crude extract and water The liquid-solid ratio (mL/g) was 15, and it was treated at a microwave power of 750 W for 10 minutes.
上述所得之第二粗萃取物利用截流分子量(MWCO)為10kDa之市售透析膜進行透析達24小時,以去除第二粗萃取物所含分子量低於10kDa的成分。然後,利用0.22μm之過濾裝置過濾第二粗萃取物,以獲得第二粗萃取物之上清液。 The second crude extract obtained above was subjected to dialysis for 24 hours using a commercially available dialysis membrane having a molecular weight cut off (MWCO) of 10 kDa to remove a component having a molecular weight of less than 10 kDa in the second crude extract. Then, the second crude extract was filtered using a 0.22 μm filter device to obtain a supernatant of the second crude extract.
之後,上述所得之第二粗萃取物在pH 3的室溫環境下進行4小時的等電點沉澱,以6000rpm之轉速離心3分鐘後,可去除83%的蛋白質。上述去除蛋白質後之第二粗萃取物,其蛋白質濃度降低為3.18g/L,總醣濃度提高為21.18g/L及42.44%(基於未進行後處理之第二粗萃取物的總量為100%),醣類回收率為92.65%(基於未進行後處理之第二粗萃取物的總量為100%)。 Thereafter, the second crude extract obtained above was subjected to isoelectric precipitation for 4 hours at room temperature of pH 3, and after centrifugation at 6000 rpm for 3 minutes, 83% of the protein was removed. The second crude extract after removing the protein has a protein concentration reduced to 3.18 g/L, and the total sugar concentration is increased to 21.18 g/L and 42.44% (based on the total amount of the second crude extract not subjected to post-treatment is 100). %), the sugar recovery was 92.65% (based on 100% of the total amount of the second crude extract not subjected to post-treatment).
然後,在上述去除蛋白質後之第二粗萃取物 中,添加最終濃度20g/L的氯化鈣(CaCl2),於4℃之環境下進行靜置4小時後,以6000rpm之轉速離心3分鐘去除沉澱的藻酸鹽。上述去除藻酸鹽後之第二粗萃取物,其總醣濃度為20.57g/L及54.85%(基於粗萃取物之總量為100%),醣類回收率為89.95%(基於粗萃取物之總量為100%)。 Then, calcium chloride (CaCl 2 ) having a final concentration of 20 g/L was added to the second crude extract after the protein removal, and after standing at 4 ° C for 4 hours, it was centrifuged at 6000 rpm for 3 minutes. The precipitated alginate is removed. The second crude extract after removing the alginate has a total sugar concentration of 20.57 g/L and 54.85% (based on 100% of the total amount of the crude extract), and the sugar recovery rate is 89.95% (based on the crude extract). The total amount is 100%).
上述所得的第二粗萃取物(300mg)經透析、過濾、及冷凍乾燥後,利用市售陰離子交換管柱(例如DEAE Sephadex A-25),以4M的氯化鈉溶液為沖提液進行層析,以獲得含有褐藻多醣的第二粗萃取物。上述層析所得的第二粗萃取物利用酚-硫酸呈色法於490nm波長下檢測光密度值,並計算醣類含量,其中層析後的第二粗萃取物的總醣濃度提高為21.18g/L及78.65%(基於粗萃取物之總量為100%),醣類回收率為78.26%(基於粗萃取物之總量為100%)。 The second crude extract (300 mg) obtained above is dialyzed, filtered, and lyophilized, and then subjected to a layer using a commercially available anion exchange column (for example, DEAE Sephadex A-25) as a solution of 4 M sodium chloride solution. Analysis to obtain a second crude extract containing fucoidan. The second crude extract obtained by the above chromatography is used to detect the optical density value at a wavelength of 490 nm by a phenol-sulfuric acid coloring method, and the sugar content is calculated, wherein the total sugar concentration of the second crude extract after chromatography is increased to 21.18 g. /L and 78.65% (based on the total amount of the crude extract is 100%), the sugar recovery rate is 78.26% (based on the total amount of the crude extract is 100%).
上述所得的第二粗萃取物利用0.025M至0.1M之過氧化氫溶液處理60分鐘後,所含的褐藻多醣之平均分子量為3.2kDa,並進行後續評估。 After the second crude extract obtained above was treated with a 0.025 M to 0.1 M hydrogen peroxide solution for 60 minutes, the average molecular weight of the fucoidan contained was 3.2 kDa, and was subjected to subsequent evaluation.
製備例2至14及比較例1至3Preparation Examples 2 to 14 and Comparative Examples 1 to 3
製備例2至11及比較例1至3係使用與製備例1相同的方式進行,不同處在於製備例2至11及比較例1至3的製程條件不同,如表1所示。 Preparation Examples 2 to 11 and Comparative Examples 1 to 3 were carried out in the same manner as in Preparation Example 1, except that the process conditions of Preparation Examples 2 to 11 and Comparative Examples 1 to 3 were different, as shown in Table 1.
1.褐藻多醣的結構1. Structure of brown algae polysaccharide
此實施例係利用電灑離子化-碰撞誘導解離-質譜/質譜法(electrospray ionization-collision induced dissociation-mass spectrometry;ESI-CID-MS/MS),對製備例1之褐藻多醣進行結構分析。根據ESI-CID-MS/MS結果(圖未繪示)顯示,製備例1之褐藻多醣的主要結構為以α-(1,3)-糖苷鍵鍵結的L-岩藻糖,且多數硫酸基在2號碳及4號碳的位置上。其次,製備例1所得之褐藻多醣具有許多分枝,主要為以(1,3)-糖苷鍵鍵結的D-半乳糖,分枝點位於岩藻糖的4號碳上,而D-半乳糖上的硫酸基主要位於4號及6號碳上,少數分布在2號碳。由上述結果可以得知,製備例1之褐藻多醣之結構為如式(I)所示,其中Gal代表以(1,3)-糖苷鍵鍵結的D-半乳糖,Fuc代表岩藻醣:
2.褐藻多醣的體外細胞試驗(I)-抗脂質生合成活性2. In vitro cell assay of brown algae polysaccharide (I) - anti-lipid biosynthesis activity
此實施例係以製備例1之褐藻多醣及比較例1之第二粗萃取物進行體外細胞試驗,以評估褐藻多醣之抗脂 質生合成的效果。 This example was subjected to an in vitro cell test using the fucoidan of Preparation Example 1 and the second crude extract of Comparative Example 1 to evaluate the anti-fat of fucoidan The effect of quality synthesis.
首先,將人類肝癌細胞株HepG2細胞〔購自財團法人食品工業發展研究所(FIRDI)生物資源保存及研究中心(BCRC),寄存編號:RM60025;另有ATCC編號:HB-8065〕培養於37℃及5% CO2的環境中,其細胞培養液包含90%(Minimum essential medium;MEM,Eagle),含有2mM L-麩胺酸(glutamine)、10%胎牛血清(fetal bovine serum;FBS)以及利用伊格爾氏平衡鹽溶液(Earle's balance salt solution;Earle's BSS)調整之1.5g/L的碳酸氫鈉(sodium bicarbonate)、0.1mM的非必需胺基酸(non-essential amino acids)與1.0mM的丙酮酸鈉(sodium pyruvate)。 First, the human hepatoma cell line HepG2 cells (purchased from the FIRDI Bioresource Conservation and Research Center (BCRC), accession number: RM60025; and another ATCC number: HB-8065) were cultured at 37 °C. In a 5% CO 2 environment, the cell culture medium contains 90% (Minimum essential medium; MEM, Eagle), containing 2 mM L-glutamine, 10% fetal bovine serum (FBS), and 1.5 g/L sodium bicarbonate adjusted with Earle's balance salt solution (Earle's balance salt solution; Earl's BSS), 0.1 mM non-essential amino acids and 1.0 mM Sodium pyruvate.
在進行評估時,HepG2細胞(1×105細胞),於HepG2細胞培養基中加入藥劑或不同濃度(20~80μg/mL)之製備例1的褐藻多醣或比較例1的第二粗萃取物1小時,再與1mM游離脂肪酸(free fatty acid,FFA;由油酸(oleic acid)與棕櫚酸(palmitic acid)以莫耳數比2:1的比例配置而成)共培養24小時。之後,利用油紅染色(oil red staining)法觀察HepG2細胞內是否有脂質堆積(呈現紅色)的現象,其結果如圖1A至圖1I所示。 At the time of evaluation, HepG2 cells (1×10 5 cells) were added to the HepG2 cell culture medium or the different concentrations (20-80 μg/mL) of the fucoidan of Preparation Example 1 or the second crude extract of Comparative Example 1 After an hour, it was co-cultured with 1 mM free fatty acid (FFA; oleic acid and palmitic acid at a molar ratio of 2:1) for 24 hours. Thereafter, the phenomenon of lipid accumulation (presenting red) in HepG2 cells was observed by oil red staining, and the results are shown in FIGS. 1A to 1I.
請參閱圖1A至圖1I,其係繪示根據本發明一實施例利用不同濃度之製備例1的褐藻多醣及比較例1的第二粗萃取物於體外處理人類肝癌細胞株HepG2細胞的顯微照片(放大倍率為40倍)。圖1A為控制組(未處理,Con)的 HepG2細胞外觀,圖1B為與FFA共培養後的HepG2細胞內脂質累積的影像,圖1C為與FFA共培養並利用吡格列酮(pioglitazon;Pio;一種糖尿病用藥)共處理後之HepG2細胞內脂質累積的影像;圖1D至圖1F分別為與FFA共培養並利用20μg/mL(圖1D)、40μg/mL(圖1E)、80μg/mL(圖1F)的比較例1之第二粗萃取物處理後的HepG2細胞內脂質累積的影像;圖1G至圖1H分別為與FFA共培養並利用20μg/mL(圖1G)、40μg/mL(圖1H)、80μg/mL(圖1I)的製備例1之褐藻多醣處理後的HepG2細胞內脂質累積的影像。 1A to FIG. 1I are diagrams showing microscopy of human hepatoma cell line HepG2 cells treated with different concentrations of the fucoidan of Preparation Example 1 and the second crude extract of Comparative Example 1 according to an embodiment of the present invention. Photo (magnification 40 times). Figure 1A shows the control group (unprocessed, Con) The appearance of HepG2 cells, FIG. 1B is an image of lipid accumulation in HepG2 cells co-cultured with FFA, and FIG. 1C shows lipid accumulation in HepG2 cells co-cultured with FFA and co-treated with pioglitazone (Pioglitazon; Pio; a diabetic drug). Image; FIG. 1D to FIG. 1F are respectively treated with the second crude extract of Comparative Example 1 co-cultured with FFA and treated with 20 μg/mL (FIG. 1D), 40 μg/mL (FIG. 1E), and 80 μg/mL (FIG. 1F). Images of lipid accumulation in HepG2 cells; Figures 1G to 1H are preparations of Preparation Example 1 co-cultured with FFA and utilized 20 μg/mL (Fig. 1G), 40 μg/mL (Fig. 1H), and 80 μg/mL (Fig. 1I), respectively. Image of lipid accumulation in HepG2 cells after treatment with fucoidan.
由圖1A至圖1C的結果顯示,相較於控制組細胞(如圖1A所示),HepG2細胞與FFA共培養後,確實產生游離脂肪酸誘發的脂質累積(如圖1B所示),利用吡格列酮處理後,可抑制肝細胞脂肪新生(de novo lipogenesis),進而減少細胞內脂質累積量(如圖1C所示)。 The results from Fig. 1A to Fig. 1C show that, compared with the control group cells (as shown in Fig. 1A), HepG2 cells co-culture with FFA did produce free fatty acid-induced lipid accumulation (as shown in Fig. 1B), using pioglitazone. After treatment, hepatic cell de novo lipogenesis can be inhibited, thereby reducing the amount of intracellular lipid accumulation (as shown in Figure 1C).
由圖1G至圖1I的結果顯示,HepG2細胞利用不同濃度之製備例1之褐藻多醣處理並與FFA共培養後,隨著第二粗萃取物使用量提高,細胞內脂質堆積量有減少的現象,代表製備例1之褐藻多醣確實具有體外抑制脂肪新生的效果。 From the results of FIG. 1G to FIG. 1I, the HepG2 cells were treated with different concentrations of the fucoidan of Preparation Example 1 and co-cultured with FFA, and the amount of intracellular lipid accumulation decreased as the amount of the second crude extract was increased. The fucoidan representative of Preparation Example 1 does have an effect of inhibiting fat regeneration in vitro.
相較之下,HepG2細胞利用不同濃度之比較例1的第二粗萃取物處理並與FFA共培養後,細胞內脂質堆積量並未隨著第二粗萃取物使用量提高而減少,如圖1D至圖1F所示。 In contrast, when HepG2 cells were treated with different concentrations of the second crude extract of Comparative Example 1 and co-cultured with FFA, the amount of intracellular lipid accumulation did not decrease as the amount of the second crude extract increased. 1D to Figure 1F.
接下來,請參閱圖2A至圖2L,其係繪示根據本 發明一實施例利用不同濃度之製備例1至製備例4的褐藻多醣於體外處理細胞的顯微照片(放大倍率為40倍)。圖2A至圖2C分別為與FFA共培養並利用20μg/mL(圖2A)、40μg/mL(圖2B)、80μg/mL(圖2C)製備例4的褐藻多醣(平均分子量107.3kDa)處理後的HepG2細胞影像(簡稱為控制組,Con)。圖2D至圖2F分別為與FFA共培養並利用20μg/mL(圖2D)、40μg/mL(圖2E)、80μg/mL(圖2F)製備例3的褐藻多醣(平均分子量68.5kDa)處理後的HepG2細胞影像(簡稱為L1)。圖2G至圖2I分別為與FFA共培養並利用20μg/mL(圖2G)、40μg/mL(圖2H)、80μg/mL(圖2I)製備例2的褐藻多醣(平均分子量31.5kDa)處理後的HepG2細胞影像(簡稱為L2)。圖2J至圖2L分別為與FFA共培養並利用20μg/mL(圖2J)、40μg/mL(圖2K)、80μg/mL(圖2L)製備例1的褐藻多醣(平均分子量3.2kDa)處理後的HepG2細胞影像(簡稱為L3)。圖2A至圖2L係利用油紅染色法觀察HepG2細胞內是否有脂質累積(呈現紅色)的現象。 Next, please refer to FIG. 2A to FIG. 2L, which are illustrated according to the present invention. MODE FOR CARRYING OUT THE INVENTION A micrograph (magnification of 40 times) of cells treated in vitro with different concentrations of the fucoidan of Preparation Examples 1 to 4 was used. 2A to 2C are respectively treated with FFA and treated with 20 μg/mL (Fig. 2A), 40 μg/mL (Fig. 2B), and 80 μg/mL (Fig. 2C) of the fucoidan of Preparation Example 4 (average molecular weight 107.3 kDa). HepG2 cell image (referred to as control group, Con). 2D to 2F are respectively treated with FFA and treated with 20 μg/mL (Fig. 2D), 40 μg/mL (Fig. 2E), and 80 μg/mL (Fig. 2F) of the fucoidan of Preparation 3 (average molecular weight 68.5 kDa). HepG2 cell image (abbreviated as L1). 2G to 2I are respectively co-cultured with FFA and treated with 20 μg/mL (Fig. 2G), 40 μg/mL (Fig. 2H), 80 μg/mL (Fig. 2I), preparation of fucoidan (average molecular weight 31.5 kDa) HepG2 cell image (abbreviated as L2). 2J to 2L are respectively co-cultured with FFA and treated with 20 μg/mL (Fig. 2J), 40 μg/mL (Fig. 2K), and 80 μg/mL (Fig. 2L) of the fucoidan (average molecular weight 3.2 kDa) of Preparation Example 1 HepG2 cell image (abbreviated as L3). Fig. 2A to Fig. 2L show the phenomenon of accumulation of lipids (presenting red) in HepG2 cells by oil red staining.
請一併參閱圖3,其係繪示圖2A至圖2L的細胞經酵素免疫分析測讀儀測試490nm波長吸收量(顯示細胞內油紅之染色量,而油紅染色量代表脂質含量)的相對吸收度長條圖(以控制組為100%計),其中縱軸為於490nm波長下檢測細胞的相對吸收度,橫軸為各處理組。圖3的圖號「*」代表該平均值±標準差相較於控制組具有統計上的顯著性差異(P<0.05),圖號「**」代表該平均值相較於控 制組具有統計上的顯著性差異(P<0.01),圖號「***」代表該平均值相較於控制組具有統計上的顯著性差異(P<0.005)(每組三重複)。 Please refer to FIG. 3 together, which shows that the cells of FIG. 2A to FIG. 2L are tested by the enzyme immunoassay tester for the absorption at a wavelength of 490 nm (showing the amount of oil red staining in the cells, and the oil red staining amount representing the lipid content). The relative absorbance bar graph (100% in the control group), wherein the vertical axis is the relative absorbance of the cells detected at a wavelength of 490 nm, and the horizontal axis is the respective treatment groups. The figure number "*" in Fig. 3 represents that the mean value ± standard deviation has a statistically significant difference ( P < 0.05) compared to the control group, and the figure number "**" represents that the average value has statistics compared to the control group. Significant differences ( P < 0.01), the figure number "***" represents that the mean is statistically significant ( P < 0.005) compared to the control group (three replicates per group).
由圖2A至圖2L的結果並搭配圖3之酵素免疫分析測讀儀測試490nm吸光值的結果顯示,褐藻多醣的平均分子量越小,抑制脂肪新生的效果就越佳。以80μg/mL的褐藻多醣為例,製備例1至製備例4的褐藻多醣抑制HepG2細胞之脂肪新生的比例分別為71.1%(圖2L)、31.6%(圖2I)、28.9%(圖2F)、28.9%(圖2C),顯示平均分子量3.2kDa之褐藻多醣(即製備例1)抑制脂肪新生的效果顯著增加。其次,圖2J至圖2L的結果並搭配圖3之酵素免疫分析測讀儀測試的結果顯示,製備例1的褐藻多醣抑制脂肪新生的效果也明顯優於吡格列酮(如圖3所示),代表平均分子量3.2kDa之褐藻多醣(即製備例1)有潛力做為肥胖治療的候選藥物。 The results of the 490 nm absorbance measured by the results of FIG. 2A to FIG. 2L and the enzyme immunoassay analyzer of FIG. 3 show that the smaller the average molecular weight of the brown algae polysaccharide, the better the effect of inhibiting fat regeneration. Taking 80 μg/mL of fucoidan as an example, the ratio of the brown algae polysaccharides of Preparation Examples 1 to 4 inhibiting the fat regeneration of HepG2 cells was 71.1% (Fig. 2L), 31.6% (Fig. 2I), 28.9% (Fig. 2F). 28.9% (Fig. 2C), the effect of the brown algae polysaccharide (i.e., Preparation Example 1) showing an average molecular weight of 3.2 kDa for inhibiting fat regeneration was significantly increased. Secondly, the results of the results of FIG. 2J to FIG. 2L and the enzyme immunoassay tester of FIG. 3 show that the effect of the fucoidan of the preparation example 1 on suppressing fat regeneration is also superior to that of pioglitazone (as shown in FIG. 3). The brown algae polysaccharide (ie, Preparation Example 1) having an average molecular weight of 3.2 kDa has potential as a drug candidate for the treatment of obesity.
相較之下,平均分子量31.5kDa至107.3kDa之褐藻多醣(即製備例2至製備例4)抑制脂肪新生的效果差異不大。 In contrast, the brown algae polysaccharide having an average molecular weight of 31.5 kDa to 107.3 kDa (i.e., Preparation Example 2 to Preparation Example 4) has little effect in inhibiting fat regeneration.
3.褐藻多醣的體外細胞試驗(II)-抗發炎活性3. In vitro cell assay of brown algae polysaccharides (II) - anti-inflammatory activity
此實施例係以製備例1之褐藻多醣及比較例1之第二粗萃取物進行體外細胞試驗,利用檢測腫瘤壞死因子(TNF)-α的含量變化,評估褐藻多醣之抗發炎的效果。 In this example, an in vitro cell test was carried out using the fucoidan of Preparation Example 1 and the second crude extract of Comparative Example 1, and the anti-inflammatory effect of fucoidan was evaluated by detecting changes in the content of tumor necrosis factor (TNF)-α.
在進行評估時,小鼠骨髓樹突細胞(Bone marrow-derived dendritic cells;BMDC;1×106細胞)先以藥劑或不同濃度(0.25μg/mL至1.0μg/mL)之製備例1的褐藻多醣或比較例1的第二粗萃取物前處理1小時,再以50μM之脂多醣(lipopolysachharide;LPS)誘發發炎反應24小時。之後,利用酵素連結免疫吸附分析法(enzyme-linked immunosorbent assay;ELISA)檢測TNF-α的含量,其結果如圖4所示。 At the time of evaluation, Bone marrow-derived dendritic cells (BMDC; 1×10 6 cells) were first treated with the drug or different concentrations (0.25 μg/mL to 1.0 μg/mL) of the brown algae of Preparation Example 1. The polysaccharide or the second crude extract of Comparative Example 1 was pretreated for 1 hour, and an inflammatory reaction was induced with 50 μM of lipopolysaccharide (LPS) for 24 hours. Thereafter, the content of TNF-α was measured by an enzyme-linked immunosorbent assay (ELISA), and the results are shown in FIG. 4 .
請參閱圖4,其係繪示根據本發明一實施例於體外經LPS誘發發炎反應的細胞利用不同濃度之製備例1的褐藻多醣及比較例1的第二粗萃取物處理後的TNF-α含量長條圖。在圖4中,縱軸代表TNF-α的含量(ng/mL),橫軸代表各處理組,包括控制組(未處理,Con)、LPS處理組(LPS)、藥物處理組(槲皮素,quercetin;Q)、比較例1的第二粗萃取物處理組(簡稱為LPS+Crude extract)以及製備例1的褐藻多醣處理組(簡稱為LPS+Fucoidan)。 Please refer to FIG. 4 , which illustrates TNF-α treated by the LPS-induced inflammatory reaction in vitro according to an embodiment of the present invention, using different concentrations of the fucoidan of Preparation Example 1 and the second crude extract of Comparative Example 1. Content bar chart. In Fig. 4, the vertical axis represents the content of TNF-α (ng/mL), and the horizontal axis represents each treatment group, including the control group (untreated, Con), the LPS treatment group (LPS), and the drug treatment group (quercetin). , quercetin; Q), the second crude extract treatment group of Comparative Example 1 (abbreviated as LPS+Crude extract) and the fucoidan treatment group of Preparation Example 1 (abbreviated as LPS+Fucoidan).
由圖4結果顯示,經LPS誘發發炎反應的BMDC細胞,利用比較例1的第二粗萃取物處理後,並沒有抑制TNF-α含量的效果,而利用1.0μg/mL比較例1的第二粗萃取物處理後,TNF-α含量反而顯著增加。然而,利用製備例1的褐藻多醣處理後,具有抑制TNF-α含量的效果。舉例而言,相較於利用0.5μg/mL比較例1的第二粗萃取物的結果,利用0.5μg/mL製備例1的褐藻多醣處理後,可降低13.3%的TNF-α含量。同理,相較於利用0.25μg/mL比較例1的第二粗萃取物的結果,利用0.25μg/mL製備例1的褐 藻多醣處理後,可降低6.7%的TNF-α含量,確實具有抗發炎活性。 The results of Fig. 4 show that the BMDC cells induced by the LPS inflammatory reaction did not inhibit the TNF-α content after treatment with the second crude extract of Comparative Example 1, but the second of Comparative Example 1 was used at 1.0 μg/mL. After treatment with the crude extract, the TNF-α content increased significantly. However, after treatment with the fucoidan of Preparation Example 1, it has an effect of inhibiting the TNF-α content. For example, compared to the result of using the second crude extract of Comparative Example 1 at 0.5 μg/mL, the treatment with 0.5 μg/mL of the fucoidan of Preparation Example 1 reduced the TNF-α content by 13.3%. Similarly, the brown of Preparation Example 1 was used at 0.25 μg/mL as compared with the result of using the second crude extract of Comparative Example 1 at 0.25 μg/mL. After treatment with algal polysaccharides, the TNF-α content of 6.7% can be reduced, and it has anti-inflammatory activity.
綜言之,本發明雖以特定種類的褐藻、特定的製程或特定的評估方式作為例示,說明本發明之褐藻多醣及其製造方法,惟本發明所屬技術領域中任何具有通常知識者可知,本發明並不限於此,在不脫離本發明之精神和範圍內,本發明之褐藻多醣及其製造方法亦可使用其他種類的褐藻、其他製程或其他的評估方式進行。舉例而言,本發明之褐藻多醣可應用到其他類型的組成物,例如用於製備抑制脂質合成及抑制促炎因子的醫藥組成物、肥胖治療的候選藥物等,以有效傳統褐藻多醣的製程並提升褐藻多醣的應用面。 In summary, although the present invention is exemplified by a specific type of brown algae, a specific process, or a specific evaluation method, the brown algae polysaccharide of the present invention and a method for producing the same are described, but any one of ordinary skill in the art to which the present invention pertains can be known. The invention is not limited thereto, and the brown algae polysaccharide of the present invention and the method for producing the same may be carried out using other types of brown algae, other processes, or other evaluation methods without departing from the spirit and scope of the invention. For example, the fucoidan polysaccharide of the present invention can be applied to other types of compositions, for example, to prepare a pharmaceutical composition for inhibiting lipid synthesis and inhibiting pro-inflammatory factors, a drug candidate for obesity treatment, etc., to effectively process the traditional fucoidan and Improve the application of brown algae polysaccharides.
由上述實施例可知,本發明之核褐藻多醣及其製造方法,其優點在於利用熱水萃取步驟併用微波輔助萃取處理及/或超聲波輔助萃取處理,不僅提高褐藻多醣之純化量,且經後處理所得之低分子量的褐藻多醣具有抑制細胞的脂質合成反應及腫瘤壞死因子(TNF)-α產生的功效,可應用於製備抑制脂質合成及抑制促炎因子的醫藥組成物。 It can be seen from the above examples that the nucleated brown algae polysaccharide of the present invention and the method for producing the same have the advantages that the hot water extraction step and the microwave assisted extraction treatment and/or the ultrasonic assisted extraction treatment not only improve the purification amount of the brown algae polysaccharide, but also the post treatment. The obtained low molecular weight fucoidan has the effects of inhibiting cell lipid synthesis reaction and tumor necrosis factor (TNF)-α production, and can be applied to prepare a pharmaceutical composition for inhibiting lipid synthesis and inhibiting proinflammatory factors.
雖然本發明已以數個實施例揭露如上,然其並非用以限定本發明,在本發明所屬技術領域中任何具有通常知識者,在不脫離本發明之精神和範圍內,當可作各種之更動與潤飾,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 While the invention has been described above in terms of several embodiments, it is not intended to limit the scope of the invention, and the invention may be practiced in various embodiments without departing from the spirit and scope of the invention. The scope of protection of the present invention is defined by the scope of the appended claims.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106146615A TWI726184B (en) | 2017-12-29 | 2017-12-29 | Polysaccharides of brown algae, method of producing the same and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106146615A TWI726184B (en) | 2017-12-29 | 2017-12-29 | Polysaccharides of brown algae, method of producing the same and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201929884A true TW201929884A (en) | 2019-08-01 |
TWI726184B TWI726184B (en) | 2021-05-01 |
Family
ID=68315826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106146615A TWI726184B (en) | 2017-12-29 | 2017-12-29 | Polysaccharides of brown algae, method of producing the same and application thereof |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI726184B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI828313B (en) * | 2022-09-13 | 2024-01-01 | 誠光生物科技股份有限公司 | Method for preparing algae polysaccharide extract |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101168570B (en) * | 2007-11-15 | 2010-05-26 | 暨南大学 | Method for degrading kelp polysaccharide sulfate |
CN101445565A (en) * | 2008-12-24 | 2009-06-03 | 江南大学 | Separation and purification method for Dunaliella salina polysaccharide |
TW201429479A (en) * | 2013-01-25 | 2014-08-01 | Yuan-Shu Lai | Use of fucoidan for treating cachexia and cancer |
TWI488866B (en) * | 2013-04-15 | 2015-06-21 | Univ Nat Kaohsiung Marine | Method for extracting seaweed polysaccharide |
CN106866834B (en) * | 2017-03-16 | 2018-01-30 | 山东省食品发酵工业研究设计院 | A kind of method and its application for preparing the efficiently fucoidin of customization molecular weight |
-
2017
- 2017-12-29 TW TW106146615A patent/TWI726184B/en active
Also Published As
Publication number | Publication date |
---|---|
TWI726184B (en) | 2021-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tan et al. | Three phase partitioning for simultaneous purification of aloe polysaccharide and protein using a single-step extraction | |
EP2823714B1 (en) | Method for producing low-ash poultry plasma protein powder by utilizing poultry blood | |
JP2013544522A5 (en) | ||
WO2017215312A1 (en) | Method for the preparation of calcium-chelating peptide using gingko nut shells | |
CN103882083B (en) | A kind of preparation method of antioxidant collagen peptide | |
CN107868810B (en) | Sea cucumber active peptide with hypoglycemic activity | |
CN103695516B (en) | Giant salamander extract and preparation method thereof | |
CN107058438A (en) | A kind of method that moringa seeds protein peptides are extracted from moringa seeds | |
Soto-Sierra et al. | Process development of enzymatically-generated algal protein hydrolysates for specialty food applications | |
CN104887541A (en) | Cosmetic containing earthworm active protein | |
CN1268220C (en) | Method for extracting maize germ oil and recovering protein by water enzyme method | |
CN104558115A (en) | Antioxidant polypeptide with Raja porosa meat protein as well as preparation method and application of antioxidant polypeptide | |
TW201929884A (en) | Polysaccharides of brown algae, method of producing the same and application thereof | |
WO2017215313A1 (en) | Method for the preparation of antioxidant peptide using gingko nut shells | |
CN109354601A (en) | The extracting method of selenoprotein in a kind of pear fruit | |
WO2020213132A1 (en) | Method for producing plasmalogen-containing functional material | |
JP2004097021A (en) | Wakame protein-containing composition, and wakame protein-containing food | |
JP7022453B2 (en) | Phycocyanin purification method | |
CN103275180B (en) | Navodon septentrionalos fish head protein antioxidant peptide as well as preparation method and application thereof | |
CN102746413B (en) | Method for preparing bee pollen polysaccharide through combining enzymolytic wall-breaking with hot-water ultrasonic extracting | |
JP2006213606A (en) | Fat decomposition-promoting agent consisting of shell of scallop or its extract | |
CN105920591B (en) | A kind of preparation method of bright mung bean superoxide dismutase liposome | |
RU2625497C1 (en) | Method for manufacturing food additive from wild plant of lupin | |
CN109811026B (en) | Collagen extraction method | |
JP2005015578A (en) | Method for producing substance containing sphingolipid and/or sphingoglycolipid |